✦ LIBER ✦

1058 ANTIVIRAL ACTIVITY AND SAFETY OF TMC435 COMBINED WITH PEGINTERFERON ALPHA-2A AND RIBAVIRIN IN PATIENTS WITH GENOTYPE 1 HEPATITIS C INFECTION WHO FAILED PREVIOUS IFN-BASED THERAPY

✍ Scribed by Marcellin, P.; Reesink, H.; Berg, T.; Cramp, M.; Flisiak, R.; Van Vlierberghe, H.; Verloes, R.; Lenz, O.; Peeters, M.; Sekar, V.; De Smedt, G.

Book ID: 122988923
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 51 KB
Volume: 50
Category: Article
ISSN: 0168-8278
DOI: 10.1016/S0168-8278(09)61060-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Functional impairment of dendritic cells

Functional impairment of dendritic cells in patients infected with hepatitis C virus genotype 1 who failed peginterferon plus ribavirin therapy

✍ Cheng-Chao Liang; Chen-Hua Liu; Yu-Li Lin; Chun-Jen Liu; Bor-Luen Chiang; Jia-Ho 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 631 KB

## Abstract Although chronic hepatitis C patients have a lower frequency and functions of dendritic cells (DCs) than healthy subjects, little is known about the serial changes in frequency and functions of DCs following anti‐viral treatment and the relationship with treatment outcomes. Twenty patie

1190 SILEN-C2: EARLY ANTIVIRAL ACTIVITY

1190 SILEN-C2: EARLY ANTIVIRAL ACTIVITY AND SAFETY OF BI 201335 COMBINED WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN (PEGIFN/RBV) IN CHRONIC HCV GENOTYPE-1 PATIENTS WITH NON-RESPONSE TO PEGIFN/RBV

✍ Sulkowski, M.; Bourliere, M.; Bronowicki, J.-P.; Streinu-Cercel, A.; Preotescu, 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 68 KB

Combination therapy of thymalfasin (thym

Combination therapy of thymalfasin (thymosin-alpha 1) and peginterferon alfa-2a in patients with chronic hepatitis C virus infection who are non-responders to standard treatment

✍ VINOD RUSTGI 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 42 KB

622 Efficacy and safety of peginterferon

622 Efficacy and safety of peginterferon alpha-2a (40KD) [PEG] plus ribavirin [RBV] 1000/1200 mg/d in genotype 1 patients with chronic hepatitis C and ‘normal’ ALT levels

✍ E. Zehnter; S. Mauss; C. John; R. Heyne; B. Möller; T. Lutz; B. Bokemeyer; R. Ki 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 117 KB

A Double-blind, randomized, placebo-cont

A Double-blind, randomized, placebo-controlled study to assess the safety, antiviral activity and pharmacokinetics of GSK2336805 when given as monotherapy and in combination with peginterferon alfa-2a and ribavirin in hepatitis C virus genotype 1-infected

✍ Gardner, Stephen; Cutrell, Amy; Elko-Simms, Cindy; Adkison, Kimberly; Hamatake, 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 221 KB

60 SILEN-C1: SUSTAINED VIROLOGIC RESPONS

60 SILEN-C1: SUSTAINED VIROLOGIC RESPONSE (SVR) AND SAFETY OF BI201335 COMBINED WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN (P/R) IN TREATMENT-NAIVE PATIENTS WITH CHRONIC GENOTYPE 1 HCV INFECTION

✍ M.S. Sulkowski; E. Ceasu; T. Asselah; F.A. Caruntu; J. Lalezari; P. Ferenci; A. 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 42 KB